source
- Inhibrx reports 9.6-month median PFS for OX40 agonist combo in phase 2 head-neck cancer trialInhibrx Biosciences presented updated data from its phase‑2 HexAgon study of the hexavalent OX40 agonist INBRX‑106 combined with Merck’s Keytruda in patients with untreated metastatic or unresectab…
- Four CDMOs to watch as biopharma outsourcing growsThe article lists four contract development and manufacturing organizations (CDMOs) that biopharma companies can partner with as demand for external development and manufacturing rises. Lonza, bas…